Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 11, 2023 at 06:45 pm IST
Share
Inhibitor Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 0.654521 million compared to USD 0.077567 million a year ago.
For the six months, net loss was USD 1.19 million compared to USD 0.176477 million a year ago. Basic loss per share from continuing operations was USD 0.01.
Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.
INHIBITOR THERAPEUTICS, INC. 